evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

138 questions · 141 findings · 9 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 27 · 19.1%GRADE not reported 4 · 2.8%Very low 25 · 17.7%Low 53 · 37.6%Moderate 27 · 19.1%High 5 · 3.5%

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

Toxicity: grade 3 or 4 fatigue · treatment of relapsed epithelial ovarian cancer

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes toxicity: grade 3 or 4 fatigue compared with chemotherapy alone (very low certainty).

1 finding from 1 review

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

Toxicity: cardiac toxicity (any grade) · treatment of relapsed epithelial ovarian cancer

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy showed no clear difference in toxicity: cardiac toxicity (any grade) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Overall survival (OS) · platinum‐sensitive recurrent EOC

Chemotherapy with bevacizumab followed by bevacizumab maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Progression‐free survival · newly‐diagnosed EOC

It is very uncertain whether chemotherapy with bevacizumab followed by maintenance bevacizumab changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).

1 finding from 1 review

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Progression‐free survival · platinum‐sensitive recurrent EOC

Chemotherapy with bevacizumab followed by bevacizumab maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Chemotherapy with bevacizumab followed by bevacizumab maintenance leads to higher any adverse event (grade ≥3) compared with chemotherapy alone (high certainty).

1 finding from 1 review

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

Chemotherapy with bevacizumab followed by maintenance bevacizumab probably leads to higher any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

Progression‐free survival · newly‐diagnosed EOC

It is very uncertain whether summary of findings table ‐ Newly‐diagnosed EOC: PARPi with… changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with… leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy alone (high certainty).

1 finding from 1 review

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

Overall survival (OS) · newly‐diagnosed EOC

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review